Pulmonary Fibrosis

​Every breath matters.  Pioneering therapies to protect lung function and transform patient lives.

Understanding the disease
What is pulmonary fibrosis?
Pulmonary fibrosis is a progressive lung disease characterized by the thickening and scarring of lung tissue. This scarring makes it increasingly difficult for oxygen to pass into the bloodstream, leading to breathing difficulties and reduced quality of life.

As the disease advances, the lungs become less elastic and more rigid, making each breath more challenging. Currently, over hundreds of thousands of people in the U.S. live with this condition. 
​Conditions We Address
Types of Pulmonary Fibrosis
Our research focuses on developing therapies for several types of pulmonary fibrotic diseases.

Idiopathic Pulmonary Fibrosis - IPF

The most common form of pulmonary fibrosis with unknown cause, characterized by progressive scarring and declining lung function.

Connective Tissue Disease - ILD

Lung fibrosis associated with autoimmune conditions such as rheumatoid arthritis, systemic sclerosis, and lupus.

Sarcoidosis

Inflammatory disease that can cause pulmonary fibrosis through the formation of granulomas in lung tissue.

Occupational Lung Disease

Fibrosis resulting from workplace exposure to silica, asbestos, coal dust, or other harmful particulates.
Our Research Efforts
Exploring A New Approach to Treatment
We are developing novel therapies that target the fundamental mechanisms driving lung fibrosis, with the goal of not just slowing progression but potentially reversing damage.
 

Targeted Pathways

Our research focuses on key biological pathways involved in fibrotic scarring, which may lead to a more precise approach to halting disease progression.

 

Enhanced Tolerability Potential

Our ultimate goal is developing therapies with improved safety profiles to help patients stay on treatment and maintain quality of life.

 

Regenerative Potential

Our innovative platform explores opportunities to not only prevent scarring but support lung tissue repair and regeneration.

Learn More About Our Science
Discover the innovative technology platform and research approach driving our pulmonary fibrosis program forward.
​IMPORTANT ​NOTICE
We are an early stage company developing a research pipeline of products addressing fibrotic diseases. The product candidates described on this website are in various stages of development and have not been approved or determined to be safe or effective by the U.S. Food and Drug Administration or any comparable regulatory authority. Nothing on this website is intended to suggest the safety, efficacy, or commercial availability of any product candidate in the United States.